Immunocore Holdings (IMCR) Depreciation & Amortization (CF) (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly Depreciation & Amortization (CF) of $948000.0 for Q1 2026, up 11.01% year-on-year from $854000.0 in Q1 2025, and up 13.67% on a QoQ basis from $834000.0 in Q4 2025.
Immunocore Holdings (IMCR) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $948000.0 the latest figure, recorded in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 11.01% year-over-year to $948000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 16.98% YoY) and the FY2025 annual result came in at $3.3 million, down 22.31% from the prior year.
- Depreciation & Amortization (CF) improved to $948000.0 in Q1 2026 per IMCR's latest filing, from $834000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for IMCR reached as high as $1.7 million in Q3 2022 and fell as low as $780000.0 in Q2 2025.
- A 5-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 38.13% — and 2024, when it grew 12.98%.
- Year by year, Depreciation & Amortization (CF) stood at $1.6 million in 2022, then slumped by 34.19% to $1.0 million in 2023, then climbed by 12.98% to $1.2 million in 2024, then decreased by 28.47% to $834000.0 in 2025, then grew by 13.67% to $948000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $948000.0, $834000.0, and $798000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn | 948,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 948,000.00 |
| Mar 31, 2026 | 948,000.00 |
| Dec 31, 2025 | 834,000.00 |
| Dec 31, 2025 | 834,000.00 |
| Sep 30, 2025 | 798,000.00 |
| Sep 30, 2025 | 798,000.00 |
| Jun 30, 2025 | 780,000.00 |
| Jun 30, 2025 | 780,000.00 |
| Mar 31, 2025 | 854,000.00 |
| Mar 31, 2025 | 854,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 992,000.00 |
| Jun 30, 2024 | 992,000.00 |
| Mar 31, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |